干眼病治疗的进展。
Advances in dry eye disease treatment.
机构信息
Scheie Eye Institute, University of Pennsylvania, Philadelphia, USA.
出版信息
Curr Opin Ophthalmol. 2019 May;30(3):166-178. doi: 10.1097/ICU.0000000000000569.
PURPOSE OF REVIEW
The prevalence and burden of dry eye disease continues to grow at a rapid pace, creating an increased need for new therapies. In a sector once limited to only a handful of treatments, clinicians now have multiple options available for patients who fail traditional therapies. This review summarizes the various treatment options available to clinicians treating complex dry eye disease patients.
RECENT FINDINGS
As we better understand the multifactorial mechanisms leading to dry eye disease, treatments increasingly focus on the amelioration of the underlying deficiencies and inflammation, rather than on transient symptomatic relief alone. Most topical medications seek to replace deficient growth factors and/or decrease inflammation on the ocular surface. The majority of new devices and procedures seek to treat meibomian gland dysfunction, with one new device stimulating tear production through utilizing the nasolacrimal reflex pathway.
SUMMARY
Clinicians have more options at their disposal in the treatment of dry eye disease than ever before, including topical medications and devices.
目的综述
干眼症的患病率和负担仍在迅速增加，这就需要更多的新疗法。在过去，干眼症的治疗方法非常有限，但现在，对于那些传统疗法失败的患者，临床医生有了更多的选择。本综述总结了目前可用于治疗复杂干眼症患者的各种治疗选择。
最近的发现
随着我们对导致干眼症的多种因素机制的理解不断加深，治疗方法越来越侧重于改善潜在的缺陷和炎症，而不仅仅是暂时的症状缓解。大多数局部药物都试图补充缺乏的生长因子和/或减少眼表的炎症。大多数新的设备和程序都试图治疗睑板腺功能障碍，有一种新的设备通过利用鼻泪管反射通路来刺激泪液产生。
总结
与以往相比，临床医生在治疗干眼症方面有更多的选择，包括局部药物和设备。
Zotero 插件